CHAMPIONS ONCOLOGY, INC.
For the period ended Apr 30, 2026. Filed Jul 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jul 27, 2026
CSBR$4.84+1.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(Dollars in Thousands Except Share and Per Share Amounts)
| Year Ended April 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Oncology revenue | $59,425 | $56,944 |
| Costs and operating expenses: | ||
| Cost of oncology revenue | 30,900 | 28,389 |
| Research and development | 9,084 | 6,825 |
| Sales and marketing | 9,318 | 7,545 |
| General and administrative | 11,152 | 9,339 |
| Loss on disposal of equipment | 111 | 293 |
| Total costs and operating expenses | 60,565 | 52,391 |
| Income (loss) from operations | (1,140) | 4,553 |
| Other income: | ||
| Other income, net | 211 | 73 |
| Income (loss) before income tax expense | (929) | 4,626 |
| Provision (benefit) for income tax | 246 | (75) |
| Net income (loss) | $(1,175) | $4,701 |
| Net income (loss) per common share outstanding | ||
| basic | $(0.08) | $0.34 |
| diluted | $(0.08) | $0.33 |
| Weighted average common shares outstanding | ||
| basic | 13,832,385 | 13,659,786 |
| diluted | 13,832,385 | 14,266,781 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.